Apimeds Pharmaceuticals US, Inc. APUS

Annual Quarterly

No annual revenue total was found in APIMEDS PHARMACEUTICALS US, INC.'s SEC filings.

Apimeds Pharmaceuticals US, Inc. (APUS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$9.0 million. As of Jun 30, 2026 it held $2.3 million in cash and investments and $161,396 in total debt.

Revenue
—
Net income (TTM)
$-58.17M
Operating cash flow (TTM)
$-13.28M
Free cash flow (TTM)
$-13.33M
EPS (TTM)
$-5.18
Dividend per share
None
Shares outstanding
12.58M
+53.5% vs prior year
Net cash
$2.12M
as of Jun 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
APUS (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Matawan, NJ
SEC filer status
, Emerging growth company
SEC CIK
1894525

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Operating income
-$11.9M
-$1.3M
Net income
-$6.0M
-$1.4M
Diluted EPS
-$0.55
-$0.18
Operating cash flow
-$8.9M
-$733,526
Free cash flow
-$9.0M
—
Total assets
$164.2M
$13,057
Total liabilities
$10.8M
$1.4M
Stockholders' equity
$153.3M
-$1.4M
Cash and investments
$3.6M
$3,455
Total debt
$169,032
—

Recent SEC filings

Form Description Filed Period
8-K Current report
Other events
 Oct 13, 2026 Oct 4, 2026
8-K Current report
Officer or director change
 Oct 1, 2026 Sep 29, 2026
8-K Current report
Other events
 Sep 29, 2026 Sep 24, 2026
8-K Current report
Change to shareholder rights, Bylaw or fiscal year change
 Sep 23, 2026 Jul 24, 2026
8-K Current report
Material agreement, Officer or director change
 Sep 11, 2026 Sep 10, 2026
8-K Current report
Material agreement
 Aug 21, 2026 Aug 19, 2026

All 130 Apimeds Pharmaceuticals US, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.